Best of ASCO® Montreal 2024: Upper GI – Dr. Nathalie Daaboul
OR
Co-Chairs
Dr. Jamil Asselah
Dr. Kim Ma
Speakers
Dr. Nathalie Daaboul
Studies/trials discussed:
- Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave150)
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
- Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
- NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)
